Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 6
1981 7
1982 17
1983 18
1984 56
1985 32
1986 64
1987 46
1988 95
1989 129
1990 84
1991 107
1992 73
1993 105
1994 80
1995 89
1996 105
1997 85
1998 84
1999 83
2000 59
2001 77
2002 97
2003 73
2004 85
2005 101
2006 89
2007 109
2008 112
2009 105
2010 105
2011 109
2012 115
2013 176
2014 149
2015 164
2016 177
2017 184
2018 158
2019 188
2020 202
2021 255
2022 270
2023 281
2024 125

Text availability

Article attribute

Article type

Publication date

Search Results

4,611 results

Results by year

Filters applied: . Clear all
Page 1
Sulbactam/Durlobactam: First Approval.
Keam SJ. Keam SJ. Drugs. 2023 Sep;83(13):1245-1252. doi: 10.1007/s40265-023-01920-6. Drugs. 2023. PMID: 37523122 Review.
Coadministration of durlobactam (a beta-lactamase inhibitor with potent activity against a broad range of serine beta-lactamases) with sulbactam (an established class A beta-lactamase inhibitor with antibacterial activity against A. baumannii) prevents sulbactam deg …
Coadministration of durlobactam (a beta-lactamase inhibitor with potent activity against a broad range of serine beta-lactamases) with su …
Sulbactam/Durlobactam.
Beninger P. Beninger P. Clin Ther. 2024 Jan;46(1):82-83. doi: 10.1016/j.clinthera.2023.11.009. Epub 2023 Dec 7. Clin Ther. 2024. PMID: 38065814 No abstract available.
In Vitro Activity of Sulbactam-Durlobactam against Global Isolates of Acinetobacter baumannii-calcoaceticus Complex Collected from 2016 to 2021.
Karlowsky JA, Hackel MA, McLeod SM, Miller AA. Karlowsky JA, et al. Antimicrob Agents Chemother. 2022 Sep 20;66(9):e0078122. doi: 10.1128/aac.00781-22. Epub 2022 Aug 25. Antimicrob Agents Chemother. 2022. PMID: 36005804 Free PMC article.
At 4 mug/mL (preliminary sulbactam-durlobactam susceptible MIC breakpoint), sulbactam-durlobactam inhibited 98.3% of all ABC isolates and >96% of sulbactam-, imipenem-, ciprofloxacin-, amikacin-, and minocycline-non-susceptible isolates; as well as colisti …
At 4 mug/mL (preliminary sulbactam-durlobactam susceptible MIC breakpoint), sulbactam-durlobactam inhibited 98.3% of all ABC i …
Population pharmacokinetics and Monte Carlo simulations of sulbactam to optimize dosage regimens in patients with ventilator-associated pneumonia caused by Acinetobacter baumannii.
Jaruratanasirikul S, Nitchot W, Wongpoowarak W, Samaeng M, Nawakitrangsan M. Jaruratanasirikul S, et al. Eur J Pharm Sci. 2019 Aug 1;136:104940. doi: 10.1016/j.ejps.2019.05.018. Epub 2019 May 25. Eur J Pharm Sci. 2019. PMID: 31132402
The aims of this study were (i) to characterize the population pharmacokinetics (PK) and (ii) to assess the efficacy of various dosage regimens of sulbactam in terms of probability of target attainment (PTA). METHODS: The PK studies were carried out following administratio …
The aims of this study were (i) to characterize the population pharmacokinetics (PK) and (ii) to assess the efficacy of various dosage regim …
Sulbactam: a beta-lactamase inhibitor.
Noguchi JK, Gill MA. Noguchi JK, et al. Clin Pharm. 1988 Jan;7(1):37-51. Clin Pharm. 1988. PMID: 3278833 Review.
The chemistry, pharmacology, microbiology, pharmacokinetics, clinical efficacy, and adverse effects of sulbactam are reviewed. Sulbactam is a competitive, irreversible beta-lactamase inhibitor. ...Sulbactam sodium is available in combination with ampicillin s …
The chemistry, pharmacology, microbiology, pharmacokinetics, clinical efficacy, and adverse effects of sulbactam are reviewed. Sul …
Sulbactam-containing beta-lactamase inhibitor combinations.
Akova M. Akova M. Clin Microbiol Infect. 2008 Jan;14 Suppl 1:185-8. doi: 10.1111/j.1469-0691.2007.01847.x. Clin Microbiol Infect. 2008. PMID: 18154545 Free article. Review.
Sulbactam irreversibly inhibits the hydrolytic activity of beta-lactamases. ...In each instance, the activity of the partner antibiotic against beta-lactamase-producing bacteria is restored. One of the particular advantages of using sulbactam-containing combinations …
Sulbactam irreversibly inhibits the hydrolytic activity of beta-lactamases. ...In each instance, the activity of the partner antibiot …
Sulbactam-durlobactam for Acinetobacter pneumonia.
Mushtaq A, Anand Raman A. Mushtaq A, et al. Lancet Infect Dis. 2023 Aug;23(8):e283. doi: 10.1016/S1473-3099(23)00450-4. Lancet Infect Dis. 2023. PMID: 37516133 No abstract available.
Sulbactam-based therapy for Acinetobacter baumannii infection: a systematic review and meta-analysis.
Chu H, Zhao L, Wang M, Liu Y, Gui T, Zhang J. Chu H, et al. Braz J Infect Dis. 2013 Jul-Aug;17(4):389-94. doi: 10.1016/j.bjid.2012.10.029. Epub 2013 Apr 19. Braz J Infect Dis. 2013. PMID: 23602463 Free PMC article. Review.
BACKGROUND: A number of studies have reported on the effectiveness of sulbactam-based therapies for Acinetobacter baumannii infection; however, there is little evidence that sulbactam-based therapies are more or less effective than alternative therapies. ...Therefor …
BACKGROUND: A number of studies have reported on the effectiveness of sulbactam-based therapies for Acinetobacter baumannii infection …
Cefoperazone and sulbactam-related eosinophilic peritonitis: a case report and literature review.
Wang Z, Li Z, Luo S, Yang Z, Xing Y, Pu C, Dong J. Wang Z, et al. J Int Med Res. 2021 Jun;49(6):3000605211025367. doi: 10.1177/03000605211025367. J Int Med Res. 2021. PMID: 34162261 Free PMC article. Review.
We excluded other possible causes and speculated that cefoperazone and sulbactam was the probable cause of EP. The patient continued treatment with cefoperazone and sulbactam for 14 days. EP resolved within 48 hours after stopping cefoperazone and sulbactam. …
We excluded other possible causes and speculated that cefoperazone and sulbactam was the probable cause of EP. The patient continued …
4,611 results

Searches related to "sulbactam"